[Cardiac remodeling after myocardial infarction : Clinical practice update]

Area of Science:

• Cardiology
• Cardiovascular Medicine
• Pathophysiology

Background:

• Heart failure is a major cause of death and hospitalization, particularly in Germany.
• Therapeutic options have improved, especially for heart failure with reduced ejection fraction.
• Cardiac remodeling, involving cellular and molecular changes, precedes clinical heart failure symptoms.

Purpose of the Study:

• To summarize current understanding of heart failure pathophysiology and management.
• To highlight the importance of early diagnosis and treatment of myocardial infarction.
• To discuss standard pharmacotherapies and emerging treatments targeting infarct healing.

Main Methods:

• Review of existing literature on heart failure, cardiac remodeling, and myocardial infarction.
• Analysis of therapeutic strategies, including pharmacotherapy and reperfusion.
• Discussion of cellular and molecular processes involved in healing after myocardial infarction.

Main Results:

• Early reperfusion therapy effectively limits infarct size and preserves left ventricular function.
• Standard pharmacotherapy (ACE inhibitors, ARBs, beta-blockers) and mineralocorticoid receptor antagonists improve outcomes.
• Ongoing research focuses on novel compounds targeting infarct healing.

Conclusions:

• Effective management of heart failure requires a multi-faceted approach, including timely intervention for myocardial infarction.
• Current therapies significantly improve outcomes, but further advancements are needed.
• Targeting infarct healing processes holds promise for future heart failure treatments.